Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Status:
Terminated
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Primary To evaluate the efficacy of satavaptan on top of diuretic drugs in reducing the
recurrence of ascites.
Secondary To evaluate the tolerability and safety of satavaptan on top of diuretic drugs over
a 52-week treatment period in participants with cirrhosis of the liver and recurrent ascites.
The one-year double blind placebo controlled period is extended up to 2 years in a long term
safety study (PASCCAL-2).